Figures & data
Table 1. Baseline characteristics of patients undergoing MWA or HR for HCC with oesophageal variceal bleeding.
Table 2. Post-operative results in two groups.
Table 3. Logistic analyses of factors associated with post-complications.
Figure 1. Typical images showing an HCC nodule treated with MWA or HR and CSPH treated with PCDV. (A) Preoperative contrast enhanced venous phase MR image (T1W1) of EV (arrow). (B) Pre-operative T1 weighted image (T1WI) of an HCC nodule (arrow). (C) Post-operative contrast enhanced arterial phase CT image of the same patient who was treated with MWA and PCDV and no enhancement was observed in the ablation zone (arrow). (D) Pre-operative contrast enhanced venous phase CT image of EV (arrow). (E) Pre-operative contrast enhanced venous phase CT image of an HCC nodule (arrow). (F) Post-operative plain CT image of the operative region of the same patient who was treated with HR and PCDV (arrow).
Figure 2. Overall survival and recurrence free survival curves for the entire study population of HCC patients with EVB who underwent MWA or HR for HCC combined with PCDV for EVB. There were no significant differences between the HR and MWA groups in terms of overall and recurrence-free survival rates.
Figure 3. Overall and recurrence-free survival curves for patients undergoing MWA or HR for HCC complicated by EVB by BCLC stage. BCLC-A patients had better overall and recurrence free survival than BCLC-B patients (p < .01).
Figure 4. Overall survival curves for subgroup analysis of patients by BCLC stage. The curves show overall survival for patients treated with HR or MWA in the (A) BCLC-A and (B) BCLC-B groups. BCLC-B patients in the HR group had better survival than those in the MWA group, and there was no significant difference between the groups for BCLC-A patients.
Table 4. Univariate and multivariate analyses of factors associated with survival and recurrence.
